7.3.4. lymphadenectomy: role extent. optimal extent lymphadectomy (lnd) established date. standard lnd mibc patients involves removal nodal tissue cranially common iliac bifurcation, ureter medial border, including internal iliac, presacral, obturator fossa external iliac nodes. lateral borders genitofemoral nerves, caudally circumflex iliac vein, lacunar ligament ln cloquet . limited lnd includes nodes true pelvis, excluding deep obturator nodes. extended lnd includes boundaries standard lnd, except cranial limit region aortic bifurcation . super-extended lnd extends cranially level inferior mesenteric artery . controversies clinical importance lnd related question whether considered staging tool, therapeutic procedure, both. 7.3.4.1. diagnostic value lymphadenectomy understand lymphatic spread mibc, two important autopsy studies performed. first study analysed 367 patients history cystectomy mibc time autopsy. total, 215 patients (59%) node-positive disease . patients 92% positive lns regional (perivesical pelvic), 72% retroperitoneal 35% abdominal. second autopsy study focused nodal yield super-extended pelvic lnd performed. substantial inter-individual differences found counts ranging 10 53 nodes . findings demonstrate limited utility node count surrogate extent dissection, supporting template-based lnd instead. addition autopsy studies, several authors adressed spread lymphatic disease performing ln mapping studies mibc patients undergoing rc (super)extended plnd [346-348]. studies demonstrated ln-positive disease present approximately 25% patients. group node- positive patients, positive lns cranial iliac bifurcation present 40% patients, however, skip ln metastasis rare (1%), seen autopsy studies. staging perspective only, studies suggest standard lnd sufficient identify nearly patients node-positive disease. 7.3.4.2. therapeutic value lymphadenectomy therapeutic value lnd topic continuous debate. assess oncological outcomes different lnd templates, systematic review including 19 studies performed . five studies compared lnd vs. lnd reported better oncological outcomes lnd group. seven twelve studies comparing (super)extended limited standard lnd reported beneficial outcome (super)extended lnd least subset patients. two studies show difference outcome extended super-extended lnd . two prospective randomised trials investigating anatomic extend lnd german lea trial us/canadien swog s1011 trial. lea trial, patients mibc (n = 346) t1g3 disease (n = 55) included. patients underwent either limited lnd (n= 203) extended lnd (n = 198). survival differences groups seen, favour extended lnd. however, extended lnd failed show significant advantage (the trial designed show absolute improvement 15% 5-year rfs extended lnd) limited lnd rfs, css, os. results swog s1011 trial comparing standard versus extended lnd, presented 2023 asco meeting, showed patients clinically localised bladder cancer median six years follow-up dfs (hr 1.10 [95%ci 0.87-1.42] p=0.4) os (hr 1.15 [95%ci 0.89-1,48] p=0.29) benefit extended lnd. does, however, increase risk side effects post-operative mortality. conclusion, based two rctâ€™s, extended lnd, associated improved survival increases risk morbidity.